Canakinumab Biosimilar – Anti-IL1B mAb – Research Grade from ProteoGenix; catalogue PX-TA1176; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Canakinumab Biosimilar, also known as Anti-IL1B mAb, is a monoclonal antibody that targets the inflammatory cytokine interleukin-1 beta (IL-1β). This biosimilar is a research grade version of Canakinumab, a FDA-approved therapeutic antibody used for the treatment of various inflammatory diseases. In this article, we will discuss the structure, activity, and potential applications of Canakinumab Biosimilar as a therapeutic antibody.
Canakinumab Biosimilar is a fully human IgG1 monoclonal antibody that is produced through recombinant DNA technology. It is composed of two heavy chains and two light chains, each with a molecular weight of approximately 50 kDa. The antibody has a typical Y-shaped structure, with two antigen-binding fragments (Fab) and one crystallizable fragment (Fc). The Fab region is responsible for binding to IL-1β, while the Fc region mediates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Canakinumab Biosimilar works by specifically binding to IL-1β and inhibiting its activity. IL-1β is a pro-inflammatory cytokine that plays a crucial role in the pathogenesis of various inflammatory diseases. By binding to IL-1β, Canakinumab Biosimilar prevents it from interacting with its receptors, thereby blocking its downstream signaling pathways. This leads to a decrease in the production of other pro-inflammatory cytokines and chemokines, ultimately reducing inflammation and associated symptoms.
Canakinumab Biosimilar has shown promising results in pre-clinical studies for the treatment of various inflammatory diseases. It has been shown to be effective in reducing inflammation and symptoms in conditions such as rheumatoid arthritis, gout, and familial Mediterranean fever. In addition, Canakinumab Biosimilar has also been investigated as a potential treatment for cardiovascular diseases, as IL-1β has been implicated in the development of atherosclerosis and heart disease.
One of the main applications of Canakinumab Biosimilar is in the treatment of inflammatory diseases. In a phase III clinical trial, Canakinumab was shown to be effective in reducing the frequency of gout flares in patients with gout. It has also been studied in patients with rheumatoid arthritis, where it was found to improve symptoms and inhibit joint damage. These results suggest that Canakinumab Biosimilar may be a promising therapeutic option for various inflammatory conditions.
Canakinumab Biosimilar has also been investigated for its potential in reducing the risk of cardiovascular events. In a large-scale clinical trial, Canakinumab was shown to significantly reduce the risk of recurrent cardiovascular events in patients with a history of heart attack. This effect was independent of its anti-inflammatory properties, suggesting that Canakinumab may have additional cardioprotective mechanisms.
As a research grade version of Canakinumab, Canakinumab Biosimilar has the potential to be used in various pre-clinical studies to further understand the role of IL-1β in different diseases. It can also be used as a comparator in clinical trials to evaluate the efficacy and safety of new therapeutic antibodies targeting IL-1β. In addition, the development of Canakinumab Biosimilar may also lead to a more affordable and accessible treatment option for patients with inflammatory diseases.
Canakinumab Biosimilar, a research grade version of Canakinumab, is a promising therapeutic antibody targeting IL-1β. Its specific binding and inhibitory effects on IL-1β make it a potential treatment option for various inflammatory diseases and cardiovascular conditions
ProteoGenix catalogue number PX-TA1176. For research use only.
Target: Canakinumab Biosimilar – Anti-IL1B mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Molecular weight: 145kDa; Buffer: PBS buffer PH7.5; Applications: WB, ELISA, Flow Cyt.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Canakinumab Biosimilar – Anti-IL1B mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
